Who is sponsoring NCT04397926?

NCT04397926 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT04397926?

Interventions in NCT04397926: Individualized neoantigen peptides vaccine.

What condition does NCT04397926 study?

NCT04397926 studies Non Small Cell Lung Cancer.

Is NCT04397926 still recruiting?

NCT04397926 is currently status unknown. Last updated 11 June 2020.

Last reviewed 2020-06-11 · How we verify

NCT04397926

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I Study of Individualized Neoantigen Peptides in the Treatment of EGFR Mutant Non-small Cell Lung Cancer

Status unknown Phase 1 Last updated 11 June 2020

What this trial tests

Phase 1 trial testing Individualized neoantigen peptides vaccine in Non Small Cell Lung Cancer in 20 participants. Status unknown.

Timeline

30 May 2020

Primary endpoint
30 May 2022

30 December 2022

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	30 May 2020
Primary completion	30 May 2022
Estimated completion	30 December 2022
Sites	1 location across China

Drugs / interventions tested

Individualized neoantigen peptides vaccine — full drug profile →

Conditions studied

Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 85, any sex, with Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Neoantigen vaccine is a new field of research in tumor immunotherapy, and some studies have been conducted with success on Melanoma and glioblastoma. Nearly 80% of lung cancers are diagnosed in an advanced stage (IIIB, and IV) and EGFR mutant non-small cell lung cancer will be resistant after targeted drug treatment. Neoantigen vaccine is a new treatment method for lung cancer, especially for patients with drug resistance.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Neoantigens: promising targets for cancer therapy.
Xie N, Shen G, Gao W, Huang Z, et al · · 2023 · cited 713× · PMID 36604431 · DOI 10.1038/s41392-022-01270-x
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.
Cooper AJ, Sequist LV, Lin JJ. · · 2022 · cited 382× · PMID 35534623 · DOI 10.1038/s41571-022-00639-9
Human immunology and immunotherapy: main achievements and challenges.
Varadé J, Magadán S, González-Fernández Á. · · 2021 · cited 123× · PMID 32879472 · DOI 10.1038/s41423-020-00530-6
Beyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines.
Stephens AJ, Burgess-Brown NA, Jiang S. · · 2021 · cited 112× · PMID 34276688 · DOI 10.3389/fimmu.2021.696791
Selecting Target Antigens for Cancer Vaccine Development.
Buonaguro L, Tagliamonte M. · · 2020 · cited 97× · PMID 33080888 · DOI 10.3390/vaccines8040615
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials.
Sobhani N, Scaggiante B, Morris R, Chai D, et al · · 2022 · cited 57× · PMID 35759856 · DOI 10.1016/j.ctrv.2022.102429
Cancer Vaccines: Antigen Selection Strategy.
Zhao Y, Baldin AV, Isayev O, Werner J, et al · · 2021 · cited 47× · PMID 33503926 · DOI 10.3390/vaccines9020085
Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle.
Starzer AM, Preusser M, Berghoff AS. · · 2022 · cited 39× · PMID 35510032 · DOI 10.1177/17588359221096219

Verify or expand the search:

Other recruiting trials for Non Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04397926 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 11 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04397926.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing